Anti-IgE and other new immunomodulation-based therapies for allergic asthma

Netherlands Journal of Medicine

Volumn 63, Issue 4, 2005, Pages 121-128

  Jonkers, R E ^a   van der Zee, J S ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anti IgE; Asthma; Immunomodulation

Indexed keywords

ALTRAKINCEPT; ANTISENSE OLIGONUCLEOTIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DNA VACCINE; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5 ANTIBODY; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OMALIZUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 12; RECOMBINANT PROTEIN;

ALLERGIC ASTHMA; ATOPY; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; EOSINOPHILIA; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; MALAISE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN E; INFUSIONS, PARENTERAL; INTERLEUKIN-12; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-4; RECEPTORS, INTERLEUKIN-5;

EID: 17644385165     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Loddenkemper R, Gibson GJ, Sibille Y. The burden of lung disease in Europe: why a European White Book on lung disease? Eur Respir J 2003;22:869.
2. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998;12:1209-18.
3. Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004 21;363:608-15.
4. Sur S, Lam J, Bouchard P, Sigounas A, Holbert D, Metzger WJ. Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. J Immunol 1996;157:4173-80.
5. Kips JC, Brusselle GJ, Joos GF, et al. Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice. Am J Respir Crit Care Med 1996;153:535-9.
6. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995;182:1527-36.
7. Keane-Myers A, Wysocka M, Trinchieri G, Wills-Karp M. Resistance to antigen-induced airway hyperresponsiveness requires endogenous production of IL-12. J Immunol 1998;161:919-26.
8. Bryan SA, O'Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2149-53.
9. Kim TS, DeKruyff RH, Rupper R, Maecker HT, Levy S, Umetsu DT. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997;158:4137-44.
10. Mauser PJ, Pitman AM, Fernandez X, et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995;152:467-72.
11. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-8.
12. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's Role Remains Uncertain as Anti-Interleukin-5 only Partially Depletes Numbers in Asthmatic Airway. Am J Respir Crit Care Med 2003;167:199-204.
13. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655-9.
14. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003;111:714-9.
15. Dorman SC, Efthimiadis A, Babirad I, et al. Sputum CD34+IL-5Ralpha+cells increase after allergen: evidence for in situ eosinophilopoiesis. Am J Respir Crit Care Med 2004;169:573-7.
16. Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 2002;169:6459-66.
17. Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002;169:6452-8.
18. Foster PS, Martinez-Moczygemba M, Huston DP, Corry DB. Interleukins-4, -5, and -13: emerging therapeutic targets in allergic disease. Pharmacol Ther 2002;94:253-64.
19. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130:487-95.
20. Ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. 'Refractory' Eosinophilic Airway Inflammation in Severe Asthma; Effect of Parenteral Corticosteroids. Am J Respir Crit Care Med 2004;170:601-5.
21. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-control led trial. Am J Respir Crit Care Med 1999;160:1816-23.
22. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107:963-70.
23. Popescu FD. New asthma drugs acting on gene expression. J Cell Mol Med 2003;7:475-86.
24. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
25. MacGlashan DWJ, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45.
26. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell Fc(epsilon)RI expression. J Allergy Clin Immunol 2003;112:1147-54.
27. Milgrom H, Fick RBJ, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999;341:1966-73.
28. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin e antibody (omalizumab). Pediatrics 2001;108:E36.
29. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61.
30. Busse W, Corren J, Lanier BQ, McAlary M, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90.
31. Hogan SP, Matthaei KI, Young JM, Koskinen A, Young IG, Foster PS. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol 1998;161:1501-9.
32. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999;189:1885-94.
33. Haselden BM, Larche M, Meng Q, et al. Late asthmatic reactions provoked by intradermal injection of T-cell peptice epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol 2001;108:394-401.
34. Ebner C. Systemic immune response to specific immunotherapy. Clin Exp Allergy 1998;28:781-3.
35. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-94.
36. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-75.
37. Muller U, Akdis CA, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-54.
38. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-54.
39. Horner AA, Raz E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J Allergy Clin Immunol 2002;110:706-12.
40. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000;30:1939-47.
41. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124-34.
42. Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004;113:235-41.
43. Branch AD. A good antisense molecule is hard to find. Trends Biochem Sci 1998;23:45-50.
44. Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997;85:721-5.